InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
NanoViricides, Inc. (NYSE American: NNVC) announced approval from the Democratic Republic of Congo’s National Ethics Committee for Health for its planned Phase II clinical trial of NV-387, a broad-spectrum antiviral targeting Mpox (hMPXV). The company is finalizing its Clinical Trial Application for submission to the Ministry of Public Health. NV-387, a host-mimetic antiviral, has shown strong preclinical results across multiple viruses including influenza, RSV, coronaviruses,…